ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Protein Intermediates Sr Bioprocess Engineer at Vaxcyte - ApplyBlast

Protein Intermediates Sr Bioprocess Engineer

Vaxcyte

1 month ago

3.9 on Glassdoor

Visp, Valais, Switzerland

Hybrid

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Vaxcyte is seeking a skilled Bioprocess Engineer to join the Manufacturing Science and Technology team, supporting microbial manufacturing operations for its vaccine portfolio from commercial readiness through ongoing production. The role involves overseeing contract manufacturing organizations in Switzerland, Italy, and Germany to ensure robust, efficient, and GMP-compliant manufacturing processes. This position requires technical leadership in process engineering, data analysis, and cross-functional collaboration to drive continuous improvement and support late-stage clinical and commercial operations.

Responsibilities

Oversee microbial manufacturing operations and CMOs for commercial vaccine production
Lead planning and execution of polysaccharide manufacturing process investigations and CAPAs
Drive continuous improvement and technology transfer for vaccine manufacturing processes

Skills

Qualifications

PhD in Bio/Chemical EngineeringPhD in Microbiology/Chemistry/BiochemistryMaster's degree in Bio/Chemical EngineeringMaster's degree in Microbiology/Chemistry/Biochemistry

About Vaxcyte

vaxcyte.com

Headquarters

San Carlos, California, United States

Company Size

51-200 employees

Founded

2013

View Profile

Vaxcyte is a clinical-stage vaccine innovation company dedicated to eliminating bacterial infections — including invasive pneumococcal disease, Group A Strep, and Shigella — using advanced chemistry and a proprietary cell-free protein synthesis platform. Its lead programs, VAX-31 (a 31-valent PCV) and VAX-24 (a 24-valent PCV), are being evaluated in Phase 3 trials for the prevention of invasive pneumococcal disease, with additional early-stage candidates targeting Group A Strep and Shigella. Vaxcyte is also investing up to $1 billion in U.S. biomanufacturing expansion to support scalable vaccine production.